HR6218

The HEAR Act of 2025, HR6218, mandates Medicare coverage for hearing aids and associated rehabilitation services. This bill directly amends Section 1861(s)(2) and (s)(8) of the Social Security Act to include "aural rehabilitation services" and "hearing aids" as covered durable medical equipment. This change expands the addressable market for hearing aid manufacturers and audiology service providers to include the entire Medicare beneficiary population, which currently lacks comprehensive hearing aid coverage. The bill defines specific services covered, including assessments, fittings, and instructional services, ensuring a full scope of care is included. The money trail for this legislation flows directly from the Medicare program to healthcare providers and manufacturers. Medicare will reimburse for hearing aids and services, creating a new, substantial revenue stream for companies operating in this space. The mechanism is direct payment for covered services and durable medical equipment. This shifts the financial burden of hearing care from individuals to the federal government for Medicare beneficiaries, significantly increasing demand and accessibility. Historically, similar expansions of Medicare coverage have led to increased demand and revenue for the covered products and services. For example, when Medicare Part D was implemented in 2006, pharmaceutical companies saw a significant increase in prescription drug sales. While direct historical precedent for hearing aid coverage at this scale is limited, the expansion of coverage for other medical devices or services consistently results in market growth. The 21st Century Cures Act in 2016, which included provisions for medical device innovation, spurred investment and growth in various medical technology sectors. While specific stock movements for hearing aid companies are not directly comparable due to the lack of prior Medicare coverage, the general trend for medical device companies after expanded coverage is positive. Specific companies stand to gain significantly. Hearing aid manufacturers like GN Group (GNRC), which owns brands like ReSound and Beltone, and WS Audiology (WSBC), parent company of Widex and Signia, will see increased sales volume. Other companies involved in audiology equipment or services, such as Sonova (SONO), which manufactures Phonak and Unitron hearing aids, and Starkey, a private company, will also benefit. While not directly hearing aid manufacturers, companies in the broader medical device sector, such as Align Technology (ALGN) through its scanner technology, or even larger players like Zimmer Biomet (ZBH), Stryker (SYK), Boston Scientific (BSX), and Medtronic (MDT) could see indirect benefits through increased R&D or acquisition opportunities in the growing audiology market. There are no clear losers from this expansion of coverage; the impact is overwhelmingly positive for the hearing health sector. This bill has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means. The sponsorship by Rep. Mullin (D-CA-15) with 6 cosponsors indicates moderate initial momentum. The next step involves committee hearings and potential markups. If it passes committee, it moves to a floor vote in the House. Given the bipartisan nature of healthcare access issues, especially for seniors, the bill has a reasonable chance of progressing. The timeline for passage is uncertain but could occur within the 119th Congress.